Skip to content 
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany. more
| Time Frame | IFRX | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 1.45% | 0.06% | -2.06% |
| 1-Month Return | -23.51% | -2.06% | -2.06% |
| 3-Month Return | -25.42% | 6.1% | 1.11% |
| 6-Month Return | 6.54% | 18.64% | 7.13% |
| 1-Year Return | -64.77% | 5.25% | 11.74% |
| 3-Year Return | -58.38% | 17.35% | 65.43% |
| 5-Year Return | -84.86% | 33.7% | 73.53% |
| 10-Year Return | -94.03% | 143.77% | 266.66% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | 63.09K | 165.79K | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":38.05,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Cost of Revenue | 812.47K | 791.26K | 627.01K | 532.26K | 3.32M | [{"date":"2020-12-31","value":24.49,"profit":true},{"date":"2021-12-31","value":23.85,"profit":true},{"date":"2022-12-31","value":18.9,"profit":true},{"date":"2023-12-31","value":16.05,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Gross Profit | (812.47K) | (791.26K) | (627.01K) | (469.17K) | (3.15M) | [{"date":"2020-12-31","value":-81247400,"profit":false},{"date":"2021-12-31","value":-79125800,"profit":false},{"date":"2022-12-31","value":-62700800,"profit":false},{"date":"2023-12-31","value":-46917300,"profit":false},{"date":"2024-12-31","value":-315125000,"profit":false}] |
| Gross Margin | - | - | - | (743.67%) | (1900.76%) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-743.67,"profit":false},{"date":"2024-12-31","value":-1900.76,"profit":false}] |
| Operating Expenses | 38.12M | 55.57M | 54.44M | 44.44M | 49.86M | [{"date":"2020-12-31","value":68.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.97,"profit":true},{"date":"2023-12-31","value":79.97,"profit":true},{"date":"2024-12-31","value":89.72,"profit":true}] |
| Operating Income | (38.93M) | (56.36M) | (55.07M) | (44.91M) | (53.01M) | [{"date":"2020-12-31","value":-3893165700,"profit":false},{"date":"2021-12-31","value":-5635999000,"profit":false},{"date":"2022-12-31","value":-5506648600,"profit":false},{"date":"2023-12-31","value":-4490809600,"profit":false},{"date":"2024-12-31","value":-5300886400,"profit":false}] |
| Total Non-Operating Income/Expense | 926.91K | 2.47M | 24.39M | 5.59M | 10.23M | [{"date":"2020-12-31","value":3.8,"profit":true},{"date":"2021-12-31","value":10.11,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":22.9,"profit":true},{"date":"2024-12-31","value":41.94,"profit":true}] |
| Pre-Tax Income | (38.74M) | (53.93M) | (30.99M) | (42.67M) | (46.06M) | [{"date":"2020-12-31","value":-3874045000,"profit":false},{"date":"2021-12-31","value":-5393385900,"profit":false},{"date":"2022-12-31","value":-3098756800,"profit":false},{"date":"2023-12-31","value":-4266752900,"profit":false},{"date":"2024-12-31","value":-4605918600,"profit":false}] |
| Income Taxes | 26.00K | 24.77K | (2.44M) | (1.00) | 5.22K | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":95.26,"profit":true},{"date":"2022-12-31","value":-9393.45,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":20.07,"profit":true}] |
| Income After Taxes | (38.77M) | (53.96M) | (28.55M) | (42.67M) | (46.06M) | [{"date":"2020-12-31","value":-3876645000,"profit":false},{"date":"2021-12-31","value":-5395862700,"profit":false},{"date":"2022-12-31","value":-2854527100,"profit":false},{"date":"2023-12-31","value":-4266752800,"profit":false},{"date":"2024-12-31","value":-4606440300,"profit":false}] |
| Income From Continuous Operations | (33.98M) | (45.63M) | (29.48M) | (34.76M) | (46.06M) | [{"date":"2020-12-31","value":-3398361400,"profit":false},{"date":"2021-12-31","value":-4563005900,"profit":false},{"date":"2022-12-31","value":-2948461100,"profit":false},{"date":"2023-12-31","value":-3476365900,"profit":false},{"date":"2024-12-31","value":-4606440300,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (38.74M) | (53.93M) | (30.99M) | (42.67M) | (46.06M) | [{"date":"2020-12-31","value":-3874045000,"profit":false},{"date":"2021-12-31","value":-5393385900,"profit":false},{"date":"2022-12-31","value":-3098756800,"profit":false},{"date":"2023-12-31","value":-4266752900,"profit":false},{"date":"2024-12-31","value":-4606440200,"profit":false}] |
| EPS (Diluted) | (1.27) | (1.10) | (0.67) | (0.79) | (0.80) | [{"date":"2020-12-31","value":-127,"profit":false},{"date":"2021-12-31","value":-110,"profit":false},{"date":"2022-12-31","value":-67,"profit":false},{"date":"2023-12-31","value":-79,"profit":false},{"date":"2024-12-31","value":-80,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| IFRX | |
|---|---|
| Cash Ratio | 2.34 |
| Current Ratio | 3.33 |
| Quick Ratio | 3.06 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| IFRX | |
|---|---|
| ROA (LTM) | -40.69% |
| ROE (LTM) | -72.49% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| IFRX | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.30 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.70 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| IFRX | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 889.87 |
| P/B | 1.06 |
| Price/FCF | NM |
| EV/R | 71.48 |
| EV/Ebitda | 0.50 |
InflaRx N.V. (IFRX) share price today is $0.8949
Yes, Indians can buy shares of InflaRx N.V. (IFRX) on Vested. To buy
Yes, you can purchase fractional shares of InflaRx N.V. (IFRX) via the Vested app. You can start investing in InflaRx N.V. (IFRX) with a minimum investment of $1.
You can invest in shares of InflaRx N.V. (IFRX) via Vested in three simple steps:
The 52-week high price of InflaRx N.V. (IFRX) is $2.77. The 52-week low price of InflaRx N.V. (IFRX) is $0.71.
The price-to-earnings (P/E) ratio of InflaRx N.V. (IFRX) is
The price-to-book (P/B) ratio of InflaRx N.V. (IFRX) is 1.06
The dividend yield of InflaRx N.V. (IFRX) is 0.00%
The market capitalization of InflaRx N.V. (IFRX) is $55.92M
The stock symbol (or ticker) of InflaRx N.V. is IFRX
Consider the share price of InflaRx N.V. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether InflaRx N.V. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in InflaRx N.V. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the InflaRx N.V. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of InflaRx N.V. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that InflaRx N.V. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
